Position in SCYX
as of Jun 30, 2026
· filed Aug 14, 2026
Position Value
$552,982
-$443,756 QoQ
Shares Held
135,868
-0.0% QoQ
Ownership
1.37%
of shares outstanding
% of Portfolio
0.11%
of 13F equity value
Holder Rank
#11
of 39 holders
Holding Since
Dec 2020
9 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in SCYX Over Time
Shares Held
Position Value (USD)
Position in Drug Manufacturers - Specialty & Generic
Healthcare · as of Jun 30, 2026DAFNA Capital Management LLC holds $22,367,669 across 6 Drug Manufacturers - Specialty & Generic names. SCYX ranks #5 (2.5% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | NBIX |
Neurocrine Biosciences Inc
|
57,769 | $9,736,387 | |
| 2 | ALKS |
Alkermes plc.
|
101,266 | $5,306,338 | |
| 3 | BCRX |
Biocryst Pharmaceuticals Inc
|
400,248 | $4,002,480 | |
| 4 | AQST |
Aquestive Therapeutics, Inc.
|
645,915 | $2,687,006 | |
| 5 | SCYX |
Scynexis Inc
This page
|
135,868 | $552,982 | |
| 6 | ADCT |
ADC Therapeutics SA
|
77,081 | $82,476 |
All Filings in SCYX
Export CSV
9 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $552,982 | 135,868 | Shares | Sole | 2026-08-14 | |
| 2026-03-31 | $996,738 | 1,086,956 | Shares | Sole | 2026-05-15 | |
| 2022-12-31 | $239,099 | 153,269 | Shares | Sole | 2023-02-14 | |
| 2022-09-30 | $957,753 | 399,064 | Shares | Sole | 2022-11-14 | |
| 2022-06-30 | $845,355 | 454,492 | Shares | Sole | 2022-08-15 | |
| 2022-03-31 | $474,056 | 121,242 | Shares | Sole | 2022-05-16 | |
| 2021-12-31 | $739,576 | 121,242 | Shares | Sole | 2022-02-14 | |
| 2021-03-31 | $713,599 | 89,874 | Shares | Sole | 2021-05-17 | |
| 2020-12-31 | $1,530,000 | 200,000 | Shares | Sole | 2021-02-16 | |
| No filing history on record for this holder in this stock. | ||||||